Ascierto PA - Search Results

1

The susceptibility CDKN2 locus may have a role on prognosis of melanoma patients.

Casula M, Budroni M, Cossu A, Ascierto PA, Mozzillo N, Canzanella S, Muggiano A, Palmieri G. Casula M, et al. Among authors: ascierto pa. Ann Oncol. 2010 Jun;21(6):1379-1380. doi: 10.1093/annonc/mdq056. Epub 2010 Mar 15. Ann Oncol. 2010. PMID: 20231302 Free article. No abstract available.

2

Epiluminescence microscopy as a useful approach in the early diagnosis of cutaneous malignant melanoma.

Ascierto PA, Satriano RA, Palmieri G, Parasole R, Bosco L, Castello G. Ascierto PA, et al. Melanoma Res. 1998 Dec;8(6):529-37. doi: 10.1097/00008390-199812000-00008. Melanoma Res. 1998. PMID: 9918415

3

Adjuvant therapy of cutaneous melanoma.

Ascierto PA, Palmieri G. Ascierto PA, et al. Lancet. 1999 Jan 23;353(9149):328. doi: 10.1016/s0140-6736(05)74894-7. Lancet. 1999. PMID: 9929057 No abstract available.

4

3-year treatment with recombinant interferon-alpha as adjuvant therapy of cutaneous malignant melanoma.

Ascierto PA, Palmieri G, Parasole R, Daponte A, Castello G. Ascierto PA, et al. Int J Mol Med. 1999 Mar;3(3):303-6. doi: 10.3892/ijmm.3.3.303. Int J Mol Med. 1999. PMID: 10028056 Clinical Trial.

5

Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. Melanoma Cooperative Group.

Palmieri G, Strazzullo M, Ascierto PA, Satriano SM, Daponte A, Castello G. Palmieri G, et al. Among authors: ascierto pa. J Clin Oncol. 1999 Jan;17(1):304-11. doi: 10.1200/JCO.1999.17.1.304. J Clin Oncol. 1999. PMID: 10458247

6

Sensitivity and specificity of epiluminescence microscopy: evaluation on a sample of 2731 excised cutaneous pigmented lesions. The Melanoma Cooperative Study.

Ascierto PA, Palmieri G, Celentano E, Parasole R, Caracò C, Daponte A, Chiofalo MG, Melucci MT, Mozzillo N, Satriano RA, Castello G. Ascierto PA, et al. Br J Dermatol. 2000 May;142(5):893-8. doi: 10.1046/j.1365-2133.2000.03468.x. Br J Dermatol. 2000. PMID: 10809845

7

Low doses interferon-alpha in the treatment of high-risk cutaneous melanoma. Melanoma Cooperative Group.

Ascierto PA, Palmieri G, Strazzullo M, Daponte A, Botti G, Satriano SM, Motti ML, Mozzillo N. Ascierto PA, et al. Ann Oncol. 2000 Apr;11(4):487-90. doi: 10.1023/a:1008375418507. Ann Oncol. 2000. PMID: 10847472 Free article. No abstract available.

8

Circulating melanoma-associated markers detected by RT-PCR in patients with classic Kaposi's sarcoma.

Palmieri G, Ascierto PA, Satriano SM, Strazzullo M, Apice G, Castello G. Palmieri G, et al. Among authors: ascierto pa. Ann Oncol. 2000 May;11(5):635-6. doi: 10.1023/a:1008397020749. Ann Oncol. 2000. PMID: 10907962 Free article. No abstract available.

9

Intermediate dose recombinant interferon-alpha as second-line treatment for patients with recurrent cutaneous melanoma who were pretreated with low dose interferon.

Ascierto PA, Daponte A, Parasole R, Perrone F, Caracò C, Melucci M, Palmieri G, Napolitano M, Mozzillo N, Castello G. Ascierto PA, et al. Cancer. 2000 Oct 1;89(7):1490-4. doi: 10.1002/1097-0142(20001001)89:7<1490::aid-cncr11>3.0.co;2-v. Cancer. 2000. PMID: 11013362 Clinical Trial.

10

Clinical significance of PCR-positive mRNA markers in peripheral blood and regional nodes of malignant melanoma patients. Melanoma Cooperative Group.

Palmieri G, Pirastu M, Strazzullo M, Ascierto PA, Satriano SM, Motti ML, Botti G, Mozzillo N, Castello G, Cossu A, Lissia A, Tanda F. Palmieri G, et al. Among authors: ascierto pa. Recent Results Cancer Res. 2001;158:200-3. doi: 10.1007/978-3-642-59537-0_20. Recent Results Cancer Res. 2001. PMID: 11092047

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

718 results

Search Page

Filters